Brandon Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brandon Miller has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Geraldine O'SUllivan Coyne
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
17 shared publications - James H. Doroshow
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, USA
17 shared publications - Deborah F. Wilsker
Frederick National Laboratory for Cancer Research 1 Clinical Pharmacodynamics Biomarker Program, Applied and Developmental Research Directorate Frederick, Maryland
16 shared publications - Ralph E. Parchment
Frederick National Laboratory for Cancer Research 1 Clinical Pharmacodynamics Biomarker Program, Applied and Developmental Research Directorate Frederick, Maryland
16 shared publications - Katherine V. Ferry-Galow
Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD
15 shared publications - Lawrence V. Rubinstein
Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
15 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16) , 1490-1497
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16) , 1490-1497
Open AccessAtezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.
- Open Access
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500055
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors
PURPOSE: We conducted a phase I trial of the combination of cisplatin with the ataxia-telangiectasia–related protein kinase inhibitor berzosertib and the poly (ADP-ribose) polymerase inhibitor (PARPi) veliparib, with the objective of creating a DNA damage response (DDR)–impaired, BRCA null–like phenotype to potentiate the antitumor activity of cisplatin. PATIENTS AND METHODS: In this open label, 3 + 3 trial design, cisplatin and berzosertib were administered intravenously on day 1 (D1) and D8, and D2 and D9, respectively, together with twice-daily oral veliparib on D1-D3 and D8-D10 in 21-day cycles. Previous platinum and PARPi therapy were permitted. A pharmacodynamic study compared tumor nuclear DDR biomarker response on C1D1 and C1D9 at the combination maximum tolerated dose (MTD). RESULTS: Fifty-three patients enrolled with 46 evaluable for response (41 with measurable disease). The MTD and recommended phase II dose (RP2D) were determined to be cisplatin 40 mg/m 2 once daily on D1/D8, berzosertib 210 mg/m 2 once daily on D2/D9, and veliparib 200 mg twice a day on D1-D3 and D8-D10. Three patients achieved confirmed partial responses (PRs; 3/41, 7.3%); two patients experienced unconfirmed PRs. Median time on study was four cycles (range, 1-25), and 35 patients (66.0%) required at least one dose reduction. The most common grade 3/4 adverse events were myelosuppressive (anemia [37.7%], thrombocytopenia [32.1%], leukopenia [24.5%], neutropenia [22.6%], lymphopenia [20.8%]); no new safety signals were observed. Adding berzosertib to veliparib/cisplatin increased the frequency of RAD51-positive tumor cells in BRCA -wildtype biopsy specimens. CONCLUSION: This combination shows antitumor activity, including in patients with and without homologous recombination–compromised tumors and those previously treated with platinum. Adding berzosertib further increases the DDR response elicited by combination cisplatin/veliparib treatment in BRCA -wildtype patients, indicating increased replication stress at the RP2D/MTD.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500055
Open AccessSafety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors
PURPOSE: We conducted a phase I trial of the combination of cisplatin with the ataxia-telangiectasia–related protein kinase inhibitor berzosertib and the poly (ADP-ribose) polymerase inhibitor (PARPi) veliparib, with the objective of creating a DNA damage response (DDR)–impaired, BRCA null–like phenotype to potentiate the antitumor activity of cisplatin. PATIENTS AND METHODS: In this open label, 3 + 3 trial design, cisplatin and berzosertib were administered intravenously on day 1 (D1) and D8, and D2 and D9, respectively, together with twice-daily oral veliparib on D1-D3 and D8-D10 in 21-day cycles. Previous platinum and PARPi therapy were permitted. A pharmacodynamic study compared tumor nuclear DDR biomarker response on C1D1 and C1D9 at the combination maximum tolerated dose (MTD). RESULTS: Fifty-three patients enrolled with 46 evaluable for response (41 with measurable disease). The MTD and recommended phase II dose (RP2D) were determined to be cisplatin 40 mg/m 2 once daily on D1/D8, berzosertib 210 mg/m 2 once daily on D2/D9, and veliparib 200 mg twice a day on D1-D3 and D8-D10. Three patients achieved confirmed partial responses (PRs; 3/41, 7.3%); two patients experienced unconfirmed PRs. Median time on study was four cycles (range, 1-25), and 35 patients (66.0%) required at least one dose reduction. The most common grade 3/4 adverse events were myelosuppressive (anemia [37.7%], thrombocytopenia [32.1%], leukopenia [24.5%], neutropenia [22.6%], lymphopenia [20.8%]); no new safety signals were observed. Adding berzosertib to veliparib/cisplatin increased the frequency of RAD51-positive tumor cells in BRCA -wildtype biopsy specimens. CONCLUSION: This combination shows antitumor activity, including in patients with and without homologous recombination–compromised tumors and those previously treated with platinum. Adding berzosertib further increases the DDR response elicited by combination cisplatin/veliparib treatment in BRCA -wildtype patients, indicating increased replication stress at the RP2D/MTD.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Prior taxane-based therapy and duration for patients receiving the nilotinib-paclitaxel combination
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Prior taxane-based therapy and duration for patients receiving the nilotinib-paclitaxel combination
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
All adverse events at least possibly attributed to study drugs
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
All adverse events at least possibly attributed to study drugs
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Dose limiting toxicities for the nilotinib-paclitaxel combination
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Dose limiting toxicities for the nilotinib-paclitaxel combination
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Paclitaxel dose intensities during DLT evaluation
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Paclitaxel dose intensities during DLT evaluation
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Peripheral neuropathy incidence following nilotinib-paclitaxel combination therapy or paclitaxel monotherapy
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Peripheral neuropathy incidence following nilotinib-paclitaxel combination therapy or paclitaxel monotherapy
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
AUC values for paclitaxel and corresponding metabolites prior to Day 1 and after Day 8 coadministration with nilotinib
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
AUC values for paclitaxel and corresponding metabolites prior to Day 1 and after Day 8 coadministration with nilotinib
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Description of methods for DLT definition, dose modification and treatment break criteria, and pharmacodynamic analyses
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Description of methods for DLT definition, dose modification and treatment break criteria, and pharmacodynamic analyses